OUR PRODUCTS WILL REVOLUTIONIZE
THE WAY MEDICINE IS PRACTICED
— AND SAVE LIVES.

Bacteria image
ContraFect's scientists are working on concepts including systemic, topical, and inhaled products that promise to improve the outcome of infections treated in the hospital, as well as prevent and treat infections contracted while in the hospital.

Current monotherapy approaches exert evolutionary pressure on pathogenic microbes, promoting the survival of mutant strains and the formation of drug-resistant pathogens. ContraFect is taking several approaches to infectious disease, one is combination therapy with Mabs and Lysins, and the second is focused on discovering and targeting conserved regions on microbes, i.e. regions that do not mutate.

LYSIN THERAPY
Utilizes a group of enzymes that have co-evolved with bacteria over millions of years so that the binding/activity sites have honed to specific portions of the cell wall that are necessary for survival, consequently, drug resistance is no longer a factor;

SYNBIOTIC THERAPY
Co-administration of Lysin with a conventional antibiotic activates, amplifies and directs therapeutic effects against pathogenic, multi drug-resistant bacteria;

SINGLE MAB THERAPY TO CONSERVED TARGETS
Mabs target specific regions of bacteria and viruses that do not mutate, enabling a single Mab to be used without generating resistance;

MAB COMBINATION THERAPY
Attacking multiple targets or pathogens simultaneously using multiple Mabs so that no single mutation or genetic reassortment can result in escape from therapy.